Market Overview

Benzinga's Microcap Movers for Thursday August 9, 2012

Related GNOM
Benzinga Market Primer: Wednesday, March 13
BGI-Shenzhen Receives Approval from Ministry of Commerce of PRC for Proposed Acquisition Of Complete Genomics
Related TLON
Talon Therapeutics Announces Strategic Review
Benzinga's Microcap Movers for Wednesday October 31, 2012

Below are highlights from Benzinga's daily coverage of small cap and microcap securities making big moves:

USEC

Shares of USEC (NASDAQ: USU), the Bethesda, MD supplier of nuclear fuel, rose 21.29% Thursday on average volume.

An report from Bloomberg Thursday says documents released today mentioned that White House U.S. Energy Secretary Steven Chu was asked by the White House to discuss USEC's bid to build an enrichment plant for uranium in Piketon, Ohio in 2011. It was one of several projects put on hold after the failure of solar panel maker Solyndra, which later sought bankruptcy protection.

USEC's application for the Piketon project is still pending with the government.

IN other news today, USEC announced that Robert Warther has been named deputy program manager for the American Centrifuge research, development and demonstration (RD&D) program.

USEC closed at $0.92 on Thursday.

Complete Genomics

Shares of Complete Genomics (NASDAQ: GNOM), the Mountain View, CA human genome sequencing company, rose 15.74% Thursday on average, volume.

Complete Genomics announced Thursday: "We will not be hosting a conference call to discuss our financial results for the second quarter, due to our ongoing review of strategic alternatives with our financial advisor Jefferies & Company".

Complete Genomics closed at $2.72 on Thursday.

Talon Therapeutics

Shares of Talon Therapeutics (TLON), the San Mateo, CA biopharmaceutical company, rose 1.03% Thursday on 8 times average volume.

Talon Therapeutics announced Thursday that Marqibo (vinCRIStine sulfate LIPOSOME injection) received accelerated approval from the U.S. Food and Drug Administration for the treatment of adult patients with Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies. This indication is based on overall response rate. Clinical benefit such as improvement in overall survival has not been verified.

Talon Therapeutics closed at $0.72 on Thursday.

The information in this article is taken from public sources, press releases, and websites that cannot always be verified. Please note that investing in microcap stocks is highly speculative. The companies mentioned here are for information purposes only. Benzinga makes no claim as to the suitability of these stocks as an investment. Neither Benzinga nor its staff recommend that you buy, sell, or hold any security. We do not offer investment advice, personalized or otherwise. Benzinga recommends that you conduct your own due diligence and consult a certified financial professional for personalized advice about your financial situation.

Posted-In: Long Ideas News Short Ideas Small Cap After-Hours Center Movers Trading Ideas

 

Most Popular

Related Articles (GNOM + TLON)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters